RIBOLIFE-B(06938) has reached a key milestone in research and development cooperation with Bayer.

RIBOLIFE-B (06938) announced that they have reached the third key milestone in their research and development collaboration with Boehringer Ingelheim (BI) on innovative treatment solutions for liver diseases, including metabolic dysfunction-related non-alcoholic steatohepatitis (NASH). NASH is a severe and progressive liver disease that can lead to fibrosis, cirrhosis, liver failure, and liver cancer, affecting over 200 million people worldwide. Despite the increasing burden of the disease, there is still a need for effective medications that can help prevent disease progression and support liver health. Through this collaboration, the company aims to expand the pipeline of potential treatment options for NASH patients in the future. Achieving this milestone further solidifies the company's position as a strategic partner for global pharmaceutical companies and highlights the commercial potential of its siRNA platform.